GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bliss GVS Pharma Ltd (BOM:506197) » Definitions » Capex-to-Operating-Income

Bliss GVS Pharma (BOM:506197) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 1991. Start your Free Trial

What is Bliss GVS Pharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Bliss GVS Pharma's Capital Expenditure for the three months ended in Mar. 2025 was ₹0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was ₹130.50 Mil.

Hence, Bliss GVS Pharma's Capex-to-Operating-Income for the three months ended in Mar. 2025 was 0.00.


Bliss GVS Pharma Capex-to-Operating-Income Historical Data

The historical data trend for Bliss GVS Pharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bliss GVS Pharma Capex-to-Operating-Income Chart

Bliss GVS Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.63 0.93 0.23 0.78

Bliss GVS Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bliss GVS Pharma's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bliss GVS Pharma's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Bliss GVS Pharma's Capex-to-Operating-Income falls into.


;
;

Bliss GVS Pharma Capex-to-Operating-Income Calculation

Bliss GVS Pharma's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-762.86) / 972.657
=0.78

Bliss GVS Pharma's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 130.499
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bliss GVS Pharma  (BOM:506197) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Bliss GVS Pharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Bliss GVS Pharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Bliss GVS Pharma Business Description

Traded in Other Exchanges
Address
Saki Vihar Road, 102, Hyde Park, Andheri (East), Mumbai, MH, IND, 400072
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from exports.

Bliss GVS Pharma Headlines

No Headlines